Iovance Biotherapeutics, Inc.
IOVA
Price:
$7.43
Market Cap:
$2.26B
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center;...[Read more]
Industry
Biotechnology
IPO Date
2010-10-15
Stock Exchange
NASDAQ
Ticker
IOVA
PE Ratio
[-5.02]
ROE
[-58.43%]
Current Ratio
[4.22]
Dividend Yield
[0%]
Enterprise Value
[2.18B]
Dividend History
The ROE as of December 2024 (TTM) for Iovance Biotherapeutics, Inc. (IOVA) is -58.43%
According to Iovance Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -58.43%. This represents a change of 289.84% compared to the average of -14.99% of the last 4 quarters.
Iovance Biotherapeutics, Inc. (IOVA) Historical ROE (quarterly & annually)
How has IOVA ROE performed in the past?
The mean historical ROE of Iovance Biotherapeutics, Inc. over the last ten years is -48.34%. The current -58.43% ROE has changed 20.88% with respect to the historical average. Over the past ten years (40 quarters), IOVA's ROE was at its highest in in the March 2015 quarter at -4.75%. The ROE was at its lowest in in the March 2020 quarter at -28.60%.
Average
-48.34%
Median
-45.96%
Minimum
-78.04%
Maximum
-26.51%
Iovance Biotherapeutics, Inc. (IOVA) ROE by Quarter and Year
Discovering the peaks and valleys of Iovance Biotherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 136.05%
Maximum Annual ROE = -26.51%
Minimum Annual Increase = -81.39%
Minimum Annual ROE = -78.04%
| Year | ROE | Change |
|---|---|---|
| 2023 | -75.95% | -2.67% |
| 2022 | -78.04% | 47.99% |
| 2021 | -52.73% | 34.59% |
| 2020 | -39.18% | -37.38% |
| 2019 | -62.57% | 136.05% |
| 2018 | -26.51% | -58.11% |
| 2017 | -63.28% | 99.70% |
| 2016 | -31.69% | 19.17% |
| 2015 | -26.59% | -0.92% |
| 2014 | -26.84% | -81.39% |
Iovance Biotherapeutics, Inc. (IOVA) Average ROE
How has IOVA ROE performed in the past?
The current ROE of Iovance Biotherapeutics, Inc. (IOVA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-68.91%
5-year avg
-61.70%
10-year avg
-48.34%
Iovance Biotherapeutics, Inc. (IOVA) ROE vs. Peers
How is IOVA’s ROE compared to its peers?
Iovance Biotherapeutics, Inc.’s ROE is less than PTC Therapeutics, Inc. (48.38%), less than Krystal Biotech, Inc. (6.34%), less than Sarepta Therapeutics, Inc. (11.83%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), less than CureVac N.V. (0%), less than Apellis Pharmaceuticals, Inc. (21.40%), greater than Mirati Therapeutics, Inc. (-103.92%), greater than CohBar, Inc. (-40.45%), greater than Rain Therapeutics Inc. (-58.44%), greater than Ocean Biomedical, Inc. (-41.33%), less than Hepion Pharmaceuticals, Inc. (75.64%), greater than null (-505.74%),
| Company | ROE | Market cap |
|---|---|---|
| 48.38% | $3.53B | |
| 6.34% | $4.59B | |
| 11.83% | $11.65B | |
| -71.78% | $6.81B | |
| 0% | $672.92M | |
| 21.40% | $4.14B | |
| -103.92% | $4.12B | |
| -40.45% | $1.57M | |
| -58.44% | $44.01M | |
| -41.33% | $20.40M | |
| 75.64% | $3.21M | |
| -505.74% | $0 |
Build a custom stock screener for Iovance Biotherapeutics, Inc. (IOVA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Iovance Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Iovance Biotherapeutics, Inc. (IOVA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Iovance Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Iovance Biotherapeutics, Inc.'s ROE?
How is the ROE calculated for Iovance Biotherapeutics, Inc. (IOVA)?
What is the highest ROE for Iovance Biotherapeutics, Inc. (IOVA)?
What is the 3-year average ROE for Iovance Biotherapeutics, Inc. (IOVA)?
What is the 5-year average ROE for Iovance Biotherapeutics, Inc. (IOVA)?
How does the current ROE for Iovance Biotherapeutics, Inc. (IOVA) compare to its historical average?